Preclinical Assets Market Expansion Outlook Through 2030 With Revenue Growth Insights

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Will Be The Estimated Market Size Of The Preclinical Assets Market By 2030?

The preclinical assets market size has experienced significant growth in recent years. It is anticipated to expand from $6.38 billion in 2025 to $7.01 billion in 2026, at a compound annual growth rate (CAGR) of 9.8%. The historical growth can be attributed to factors including increasing pharmaceutical r&d investments, the expansion of early-stage drug discovery programs, a growing reliance on animal-based testing, a rising demand for safety data generation, and the increasing outsourcing of preclinical studies.

The preclinical assets market is poised for significant expansion over the coming years. Projections indicate it will reach $10.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period stems from factors such as the greater acceptance of human-relevant preclinical models, a heightened need for faster drug development timelines, the broadening of personalized medicine pipelines, the increasing incorporation of AI into preclinical investigations, and a stronger regulatory focus on the reliability of data. Key trends for the forecast period encompass a surge in the utilization of advanced preclinical models, the expanding embrace of patient-derived xenograft and organoid models, an escalating demand for integrated preclinical services, an enlargement of safety and toxicology studies, and an intensified concentration on translational research.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

What Major Growth Factors Are Impacting The Preclinical Assets Market?

The growing need to curb clinical trial costs is projected to stimulate the growth of the preclinical asset market moving forward. Clinical trial costs involve the expenditures related to planning, conducting, and managing a clinical trial to assess the safety, efficacy, and potential benefits of new medical interventions, such as drugs, medical devices, or treatment protocols. These trials are vital for providing insights into the safety, efficacy, and potential side effects of preclinical assets, thus helping to validate their therapeutic potential in human subjects. For example, in February 2023, Genetic Engineering and Biotechnology News, a US-based platform offering the latest information on genetic engineering and biotechnology, indicated that the cost of developing a new drug among the top 20 global biopharma companies surged by 15%, from $298 million in 2022 to approximately $2.3 billion in 2023, a figure that includes expenses incurred from developing a drug through clinical trials. Consequently, the increasing necessity to manage clinical trial costs is propelling the expansion of the preclinical assets market.

Which Segment Divisions Form The Structure Of The Preclinical Assets Market?

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing

3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations

5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

What Trends Are Driving Changes In The Preclinical Assets Market?

Leading firms within the precision psychiatry market are concentrating on creating novel therapies, specifically prescription digital therapeutics, to facilitate tailored and data-informed treatment approaches for psychiatric conditions. Such a therapeutic is a software-driven medical intervention, prescribed by clinicians, which provides behavioral therapy modules founded on evidence via a mobile device to boost symptom alleviation and adherence to treatment. An example of this is the August 2024 launch of Rejoyn by Otsuka Precision Health Inc. (a US-based precision health division of Otsuka Holdings) and Click Therapeutics Inc. (a US-based digital therapeutics firm). Rejoyn stands as the sole prescription digital therapeutic to receive clearance from the United States Food and Drug Administration (FDA) for the supplementary management of major depressive disorder (MDD) symptoms. This product offers a six-week cognitive-emotional training program that merges the emotional faces memory task with skill modules based on cognitive behavioral therapy (CBT), also facilitating digital prescriptions, patient involvement, and remote oversight. The introduction of Rejoyn signifies a notable advancement in Precision Psychiatry, illustrating the potential of digital therapeutics to augment pharmacological interventions for providing individualized care. Furthermore, it sets the stage for wider acceptance of software-dependent interventions that incorporate real-time patient information to enhance therapeutic results and patient compliance.

Who Are The Prominent Players Across The Preclinical Assets Market?

Major companies operating in the preclinical assets market are Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

Access The Complete Preclinical Assets Market Report:

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

Which Geographic Region Represents The Largest Preclinical Assets Market Share?

North America was the largest region in the preclinical assets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Preclinical Assets Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12600&type=smp

Browse Through More Reports Similar to the Global Preclinical Assets Market 2026, By The Business Research Company

Psychiatrists Market 2026

https://www.thebusinessresearchcompany.com/report/psychiatrists-market

Precision Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/precision-diagnostics-global-market-report

Digital Psychotherapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-psychotherapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795